News

To help ensure you are doing all you can to prevent a security breach, we asked the experts to weigh in. Here they identify four of the biggest mistakes health plans are making.

In this commentary, an industry insider shares his 2016 predictions for healthcare. Do you agree?

A new study of a pediatric ACO serving approximately 300,000 Medicaid-eligible children in Ohio evaluated whether financial incentives influence physician behavior.

For decades, administrative costs for health plans have stalled. Today’s healthcare market is full of opportunities to trim the fat.

The precision medicine uptake is not as fast as predicted in healthcare organizations, but academic medical centers are jumping on board faster than others.

FDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis.

A new survey reveals what employers' medical plans are doing to rein in specialty drug cost and utilization.

It is young white males who are dying from drug overdoses in the U.S., according to a New York Times analysis of death certificates.

Abbott's Compounding Pharmacy in Berkeley, Calif., is voluntarily recalling all unexpired lots of sterile compounded products because of lack of sterility assurance.

FDA has approved an expanded age indication for Hib vaccine (Hiberix, GlaxoSmithKine).

As the healthcare industry changes, health plan executives must master new skills.

While diabetes, particularly type 2, remains an epidemic, the number of new diagnoses has begun to slow. Here are some developments contributing to the decrease.

There is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine.

FDA advisers recommended approval of the first long-acting, subdermal buprenorphine implant (Probuphine, Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals) for the maintenance treatment of opioid addiction.

New research: Hospitals risk millions from failure to provide consumer-friendly mobile apps. How to achieve exceptional consumer experience.

Broader exchange of ideas for diabetes health management and related programs may result in more efficient community-based programs with a wider impact.

Pharmaceutical companies are battling state legislation that would require state programs such as Medicaid to pay no more than other Federal government programs for drugs.

Independence reaches a deal with NantHealth to cover next-generation whole genome sequences for a variety of cancers.

Analysts ponder what Aetna’s leave from AHIP means for the industry and the powerhouse trade association.

After a death and a hospitalized patient, FDA is cautioning that differences in dosing regimens between the 2 oral formulations of Merck’s antifungal drug Noxafil (posaconazole) have resulted in dosing errors.

New initiative poised to be a model for health plan providers to foster improved collaboration between pharmacists and physicians.

Don't let your healthcare organization's information be compromised. Watch out for these common mistakes.

Payers weigh the benefits of using their own resources to develop a specialty pharmacy or contracting outside for services.

Innovation will be necessary to compete for consumers in the new market environment. Using data effectively can help plans stand out.

Gilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug.

The Commonwealth Fund examined the effects of the ACA’s Medicaid expansion on low income adults in three states that took different approaches to the law. Here’s what they found.

While forming risk-based entities among Medicaid providers could be an effective way to better manage the care of low-income populations, the risk of unintended consequences cannot be ignored. A key hedge against these consequences is better use of patient data.